Get the Stockscreener App
2.39
2.45%
-0.06
Ac Immune Sa stock is traded at $2.39, with a volume of 126.85K.
It is down -2.45% in the last 24 hours and down -9.81% over the past month.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.45
Open:
$2.45
24h Volume:
126.85K
Relative Volume:
0.67
Market Cap:
$237.63M
Revenue:
$4.60M
Net Income/Loss:
$-82.31M
P/E Ratio:
-2.9139
EPS:
-0.8202
Net Cash Flow:
$-87.79M
1W Performance:
-4.40%
1M Performance:
-9.81%
6M Performance:
-22.15%
1Y Performance:
-19.26%
1-Day Range:
$2.38
$2.47
1-Week Range:
$2.35
$2.50
52-Week Range:
$2.095
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.39 | 237.63M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune SA (HAM:IMR) Stock Price, Trades & News - GuruFocus
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Best Momentum Stock to Buy for September 30th - Zacks Investment Research
Average basic shares outstanding of AC Immune SA – HAN:IMR - TradingView
Long term debt to total equity ratio of AC Immune SA – HAN:IMR - tradingview.com
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals - Yahoo Finance
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
AC Immune says ACI-7104 shows durable immunogenicity - The Pharma Letter
AC Immune (NasdaqGM:ACIU) Stock Forecast & Analyst Predictions - Simply Wall Street
AC Immune SA (ACIU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response - Benzinga
AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports positive phase 2 trial results for ACI-7104 - Investing.com
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com UK
Experimental Parkinson’s treatment from AC Immune (NASDAQ: ACIU) sparks immune response in early trial - Stock Titan
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - Yahoo Finance UK
After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - GlobeNewswire
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
AC Immune SA Share PriceACIU, RNS News, Articles, Quotes, & Charts (NASDAQ:ACIU) - Proactive financial news
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - Stock Titan
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune stock gains on early Phase 1 trial results - Investing.com India
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ac Immune Sa Stock (ACIU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ANDREA M.A PFEIFER | Director |
May 15 '26 |
Proposed Sale |
2.80 |
20,000 |
56,000 |
0 |
| ANDREA M.A PFEIFER | Officer |
Apr 15 '26 |
Proposed Sale |
3.19 |
10,000 |
31,900 |
0 |
| ANDREA M.A PFEIFER | Officer |
Jan 15 '26 |
Proposed Sale |
3.67 |
30,000 |
110,100 |
0 |
| ANDREA M.A PFEIFER | Officer |
Oct 03 '25 |
Proposed Sale |
3.13 |
45,000 |
140,850 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):